1. Generics Bulletin

Torrent Sees US Sales Decline By 20%

As Company Launches 10 Products In India In Q3 FY22

 
• By Akriti Seth

India’s Torrent has seen back-to-back decline in its US business, reporting a 20% drop in revenues in Q3 FY22 alone, as new launches are predicted to come to the rescue in the US market. The company remains stable domestically with new launches as it sees 15% growth in the Indian market.

SOS
Torrent’s US business can be rescued with new launches • Source: Alamy

Torrent Pharmaceuticals Ltd.has reported a 20% drop in its US revenues to INR2.35bn ($31.75m) for the firm’s financial third quarter ended 31 December 2021. The Indian company cited price erosion in the base business and a lack of new approvals pending re-inspection of facilities as the reason for the double-digit drop in its US sales.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products